

## Synthesis of (-)-Deoxoprosophylline, (+)-2-*epi*-Deoxoprosopinine, and (2*R*,3*R*)- and (2*R*,3*S*)-3-Hydroxypipecolic Acids from D-Glycals

Hari Prasad Kokatla, Rima Lahiri, Pavan K. Kancharla, Venkata Ramana Doddi, and Yashwant D. Vankar\*

Department of Chemistry, Indian Institute of Technology Kanpur 208 016, India

vankar@iitk.ac.in

Received March 18, 2010



New syntheses of (-)-deoxoprosophylline, (+)-2-*epi*deoxoprosopinine, and (2R,3R)- and (2R,3S)-3-hydroxypipecolic acids are reported. Utilization of the chiral functionalities of Perlin aldehydes, derived from 3,4,6tri-*O*-benzyl glycals, has been done along with chemoselective saturation of olefins and reductive aminations as key steps.

A number of naturally occurring piperidine alkaloids and their derivatives exhibit important biological properties. In addition, a number of other N-heterocyclic compounds have also been found to be useful as pharmaceuticals and agrochemicals.<sup>1</sup> In particular, hydroxylated pyrrolidine, piperidine, pyrrolizidine, and indolizidine alkaloids and their derivatives have received extensive attention due to their well-established action as glycosidase inhibitors.<sup>2</sup> Among piperidine alkaloids, *Prosopis africana* alkaloids<sup>3</sup> such as

**4608** J. Org. Chem. **2010**, 75, 4608–4611



FIGURE 1. Structures of prosophyllines and related molecules.

1-3 and Cassia<sup>4</sup> alkaloid 4 (Figure 1) are medicinally important as they possess anesthetic, analgesic, and antibiotic activities.<sup>5</sup> (-)-Deoxoprosophylline (1), (-)-prosophylline, and (+)-2-epi-deoxoprosopinine (3), having interesting structural features of 2,6-cis-disubstituted piperidin-3-ol, were isolated from the leaves of *Prosopis africana* Taub.<sup>3</sup> These contain a hydrophobic aliphatic tail and a hydrophilic headgroup and thus could be assumed to resemble the cyclic structure of safingol (6) and sphingosine (7).<sup>6</sup> While the polar headgroup is essential for glycosidase inhibition,<sup>7</sup> the aliphatic long chain facilitates lipid membrane penetration. These distinctive properties enhance the therapeutic potential of these compounds for the treatment of diseases such as diabetes, viral infection, and cancer. Due to these promising biological activities and structural features, many newer approaches toward the synthesis of these molecules have been developed. There are several reports in literature for the synthesis of these molecules starting from chiral building blocks such as amino acids,<sup>8</sup> carbohydrates,<sup>9</sup> vitamin C,<sup>10</sup> and malic acid.<sup>11</sup> However, either some of these building blocks are expensive or the syntheses may require many steps. Thus, for example, synthesis of (+)-deoxoprosophylline from D-glycals was achieved in 15–16 steps.<sup>9a-c</sup> Further, only one report is available for the synthesis of the target

General reviews: Comprehensive Heterocyclic Chemistry; Katritzky,
 A. R., Rees, C. W., Eds.; Pergamon Press: New York, 1984. Advances in Heterocyclic Chemistry; Katritzky, A. R., Ed.; Academic Press: New York, 1963–1996.

<sup>(2) (</sup>a) Asano, N.; Nash, R. J.; Molyneux, R. J.; Fleet, G. W. J. *Tetra*hedron: Asymmetry **2000**, 11, 1645. (b) Winchester, B.; Daher, S. A.; Carpenter, N. C.; Cenci di Bello, I.; Choi, S. S.; Fairbanks, A. J.; Fleet, G. W. J. J. Biochem. **1993**, 290, 743 and references cited therein. (c) Heightman, T. D.; Vasella, A. T. Angew. Chem., Int. Ed. **1999**, 38, 750.

<sup>(3) (</sup>a) Ratle, G.; Monseur, X.; Das, B.; Yassi, J.; Khuong-Huu, Q.; Goutarel, R. *Bull. Soc. Chim. Fr.* **1966**, 2945. (b) Khuong-Huu, Q.; Ratle, G.; Monseur, X.; Goutrarel, R. *Bull. Soc. Chim. Belg.* **1972**, *81*, 425. (c) Cook, G. R.; Beholz, L. G.; Stille, J. R. *Tetrahedron Lett.* **1994**, *35*, 1669 and references cited therein.

<sup>(4)</sup> Highet, R. J. J. Org. Chem. 1964, 29, 471.

<sup>(5) (</sup>a) Sansores-Peraza, P.; Rosado-allado, M.; Brito-Loeza, W.; Mena-Rejon, G. J.; Quijano, L. *Fitoteirapia* **2000**, *71*, 690. (b) Ahmad, A.; Khan, K. A.; Ahmad, V. U.; Qazi, S. *Planta Med.* **1986**, *4*, 285. (c) Astudillo, S. L.; Jurgens, S. K.; Schmeda-Hirschmann, G.; Griffith, G. A.; Holt, D. H.; Jenkins, P. R. *Planta Med.* **1999**, *65*, 161. (d) Aguinaldo, A. M.; Read, R. W. *Phytochemistry* **1990**, *29*, 2309.

<sup>(6) (</sup>a) Kokatla, H. P.; Sagar, R.; Vankar, Y. D. Tetrahedron Lett. 2008, 49, 4728.

<sup>(7) (</sup>a) Asano, N. *Glycobiology* **2003**, *13*, 93. (b) Junge, B.; Matzke, M.; Stoltefuss, J. In *Handbook of Experimental Pharmacology*; Kuhlmann, J., Puls, W., Eds.; Springer: Berlin, 1996; Vol. 119, p 411. (c) Winchester, B.; Fleet, G. W. J. *Glycobiology* **1992**, *2*, 199.

<sup>(8) (</sup>a) Fuhshuku, K.; Mori, K. Tetrahedron: Asymmetry 2007, 18, 2104.
(b) Andrés, J. M.; Pedrosa, R.; Pérez-Encabo, A. Eur. J. Org. Chem. 2007, 1803. (c) Jourdant, A.; Zhu, J. Heterocycles 2004, 64, 249. (d) Datta, A.; Kumar, J. S. R.; Roy, S. Tetrahedron 2001, 57, 1169. (e) Jourdant, A.; Zhu, J. Tetrahedron Lett. 2001, 42, 3431. (f) Ojima, I.; Vidal, E. S. J. Org. Chem. 1998, 63, 7999. (g) Kadota, I.; Kawada, M.; Muramatsu, Y.; Yamamoto, Y. Tetrahedron: Asymmetry 1997, 8, 3887. (h) Saitoh, Y.; Moriyama, Y.; Takahashi, T.; Khuoung-Huu, Q. Tetrahedron Lett. 1980, 21, 75.

<sup>(9) (</sup>a) Tzanetou, E. N.; Kasiotis, K. M.; Magiatis, P.; Haroutounian, S. A. *Molecules* 2007, *12*, 735. (b) Dransfield, P. J.; Gore, P. M.; Prokeš, I.; Shipman, M.; Slawin, A. M. Z. *Org. Biomol. Chem.* 2003, *1*, 2723.
(c) Dransfield, P. J.; Gore, P. M.; Shipman, M.; Slawin, A. M. Z. *Chem. Commun.* 2002, 150. (d) Herdeis, C.; Telser, J. *Eur. J. Org. Chem.* 1999, 1407.
(e) Takao, K.; Nigawara, Y.; Nishino, E.; Takagi, I.; Maeda, K.; Tadano, K.; Ogawa, S. *Tetrahedron* 1994, *50*, 5681.

<sup>(10)</sup> Herdeis, C.; Tesler, J. Eur. J. Org. Chem. 1999, 1407.

<sup>(11)</sup> Yuasa, Y.; Ando, J.; Shibuya, S. J. Chem. Soc., Perkin Trans. 1 1996, 793.



FIGURE 2. Structures of pipecolic acids and related molecules.

molecule 1 from D-glucose and that requires 24 steps.<sup>9e</sup> An improved asymmetric synthesis of (+)-2-*epi*-dexoprosopinine (**3**) was reported by Enders et al. in 11 steps by using SAMP hydrazone as a chiral auxiliary.<sup>12a</sup> More recently, Huang et al.<sup>12b</sup> reported the synthesis of **3** using SmI<sub>2</sub>-mediated coupling of (*S*)-3-silyloxyglutarimide.<sup>12b</sup>

The 3-hydroxypipecolic acid motif is present in a wide variety of natural and unnatural products.<sup>13</sup> These molecules are considered as homologated forms of the hydroxyproline moiety or constrained analogues of serine. In general, 3-hydroxypipecolic acid 7 (Figure 2) and its stereoisomers 8 and 9 are useful chiral building blocks for the synthesis of a variety of pharmaceutically important molecules. Thus, the structural features of the *cis* isomer 7 are present in the naturally occurring antitumor antibiotic tetrazomine<sup>14</sup> 11. On the other hand, the *trans* isomer 8 is a precursor for potent  $\alpha$ -mannosidase inhibitor (–)-swainsonine<sup>15</sup> and is also found to be an integral part of the potent antimalarial agent febrifugine (12).<sup>16</sup>

Due to the medicinal importance of 3-hydroxypipecolic acids, synthetic efforts toward such molecules have gained much attention.<sup>17</sup> The usual pathways can be classified as (i) an asymmetric synthesis approach,<sup>18</sup> (ii) a chiron approach,<sup>19,20</sup>

(14) Scott, J. D.; Tippie, T. N.; Williams, R. M. *Tetrahedron Lett.* **1998**, *39*, 3659.

(15) Ferreira, F.; Greck, C.; Genet, J.-P. Bull. Soc. Chim. Fr. 1997, 134, 615.

(16) (a) Kuehl, F. A., Jr.; Spencer, C. F.; Folkers, K. J. Am. Chem. Soc. **1948**, 70, 2091. (b) Kobayashi, Sh.; Ueno, M.; Suzuki, R. Tetrahedron Lett. **1999**, 40, 2175. (c) Jourdant, A.; Zhu, J. Tetrahedron Lett. **2000**, 41, 7033 and references cited therein.

(17) (a) McNaughton-Smith, G; Hanessian, S.; Lombart, H. G.; Lubell,
W. D. *Tetrahedron* 1997, 53, 12789. (b) Copeland, T. D.; Wondrak, E. M.;
Toszer, J.; Roberts, M. M.; Oraszan, S. *Biochem. Biophys. Res. Commun.* 1990, 169, 310. (c) Quibell, M.; Benn, A.; Flinn, N.; Monk, T.; Ramjee, M.;
Wang, Y.; Watts, J. *Bioorg. Med. Chem.* 2004, 12, 5689.

(18) (a) Kumar, P.; Boda, M., S. J. Org. Chem. 2005, 70, 360. (b)
 Horikawa, M.; Busch-Petersen, J.; Corey, E. J. Tetrahedron. Lett. 1999, 40, 3843. (c) Greck, C.; Ferreira, F.; Genêt, J. P. Tetrahedron. Lett. 1996, 47, 2031.

(19) (a) Dutta, A.; Liang, N. J. Org. Chem. 2005, 70, 10182. (b) Takahata,
H.; Banba, Y.; Ouchi, H.; Nemoto, H.; Kato, A.; Adachi, I. J. Org. Chem.
2003, 66, 3603. (c) Takahata, H.; Banba, Y.; Ouchi, H.; Nemoto, H. Org. Lett. 2003, 5, 2527.



SCHEME 1. Retrosynthetic Analysis of (-)-Dexoprosophylline

SCHEME 2. Retrosynthetic Analysis of 3-Hydroxypipecolic Acids



and (iii) enzymatic resolution.<sup>21</sup> While asymmetric synthesis approaches involve either dihydroxylation or epoxidation followed by nucleophilic attack with nitrogen, chiron approaches utilize chiral pool starting materials such as chiral amino acids and carbohydrates.<sup>20</sup>

In continuation of our recent work on functionalization of D-glycals toward bioactive natural products,<sup>22</sup> we have reported<sup>6</sup> the synthesis of safingol and its stereoisomer from Perlin aldehydes<sup>23</sup> derived from D-glycals. In this paper, we report the synthesis of (–)-dexoprosophylline **1**, (+)-2-*epi*-dexoprosophine **3**, and 3-hydroxypipecolic acids from Perlin aldehydes. Our retrosynthetic analysis toward the synthesis of (–)-dexoprosophylline (**1**) and (+)-2-*epi*-dexoprosophine (**3**) is shown in Scheme 1. The target molecules can be prepared from azido ketones by reductive cyclization, which in turn, can be prepared from the corresponding aldehydes by Grignard reaction followed by oxidation. These aldehydes can be easily prepared from Perlin aldehydes which can be obtained from D-glycals upon acid hydrolysis.<sup>23</sup>

The hydroxy pipecolic acids can be prepared (Scheme 2) from the benzyl-protected piperidines, which can be obtained from the dimesylates derived from Perlin aldehydes.

The synthetic approaches toward 1 and 3 are outlined in Scheme 3. Thus, 3,4,6-tri-*O*-benzylated glycals 13 and 14 were subjected to Perlin hydrolysis<sup>23</sup> followed by acetylation to afford the respective *trans*-enals 15 and 16 in 92% and 52% yields, respectively. Chemoselective saturation of double bond in 15 and 16 was carried out under  $H_2/Pd-C$  conditions to give 17 and 18 in good yields. The so-obtained aldehydes

<sup>(12) (</sup>a) Enders, D.; Kirchhoff, J. H. Synthesis 2000, 2099. (b) Wei, B.-G.; Chen, J.; Huang, P.-Q. Tetrahedron 2006, 62, 190.

<sup>(13) (</sup>a) Schneider, M. J. Pyridine and Piperidine Alkaloids: Chemistry and Pharmacology. In *Alkaloids: Chemical and Biological Perspectives*; Pelletier, S. W., Ed.; Pergamon: Oxford, 1996; Vol. 10, pp 155–299. (b) Fodor, G. B.; Colasanti, B. The Pyridine and Piperidine Alkaloids: Chemistry and Pharmacology. In *Alkaloids: Chemical and Biological Perspectives*; Pelletier, S. W., Ed.; Wiley-Interscience: New York, 1985; Vol. 3, pp 1–90. (14) Scott, J. D.; Tippie, T. N.; Williams, R. M. *Tetrahedron Lett.* **1998**,

<sup>(20) (</sup>a) Kalamkar, N. B.; Kasture, V. M.; Dhavale, D. D. J. Org. Chem.
2008, 73, 3619. (b) Chiou, W.-H.; Lin, G.-H.; Liang, C.-W. J. Org. Chem.
2010, 75, 1748. (c) Kumar, P. S.; Benerjee, A.; Baskaran, S. Angew. Chem., Int. Ed. 2010, 49, 804.

<sup>(21) (</sup>a) Scott, J. D.; Williams, R. M. *Tetrahedron Lett.* **2000**, *41*, 8413. (b) Knight, D. W.; Lewis, N.; Share, A. C.; Haigh, D. *Tetrahedron: Asymmetry* **1993**, *4*, 625.

<sup>(22) (</sup>a) Rawal, G. K.; Kumar, A.; Tawar, U.; Vankar, Y. D. Org. Lett.
2007, 9, 5171. (b) Rawal, G. K.; Rani, S; Madhusudanan, K. P.; Vankar,
Y. D. Synthesis 2007, 294. (c) Rawal, G., K.; Rani, S.; Kumar, A.; Vankar,
Y. D. Tetrahedron Lett. 2006, 47, 9117. (d) Reddy, G. B.; Madhusudanan,
K. P.; Vankar, Y. D. J. Org. Chem. 2004, 69, 2630. (e) Agarwal, A.; Rani, S.;
Vankar, Y. D. J. Org. Chem. 2004, 69, 6137.

<sup>(23) (</sup>a) Gonzalez, F.; Lesage, S.; Perlin, A. S. *Carbohydr. Res.* 1975, 42, 267. (b) Sagar, R.; Pathak, R.; Shaw, A. K. *Carbohydr. Res.* 2004, 339, 2031.
(c) Hirata, N.; Yamagiwa, Y.; Kamikawa, T. *J. Chem. Soc., Perkin Trans. 1* 1991, 2279.

SCHEME 3. Synthesis (-)-Deoxoprosophylline and (+)-2-*epi*-Dexoprosopinine



were subjected to Grignard reaction using dodecylmagnesium bromide at -78 °C in Et<sub>2</sub>O to give a diastereomeric mixture of alcohol at the C-6 center. The free hydroxyl was consecutively oxidized using the  $CrO_3$ ,  $Ac_2O$ , pyridine system<sup>24</sup> to give ketones 19 and 20 in 71% and 69% yields, respectively. Methanolysis of acetates 19 and 20 with NaOMe/MeOH gave the hydroxyl ketones 21 and 22, respectively, in good yields. Conversion of the C-2 hydroxyl group as mesylate followed by an  $S_N$  displacement with sodium azide gave the products 25 and 26 with complete inversion of configuration in excellent yields. These azido ketones underwent reduction and reductive ring closure followed by debenzylation in one step when they were treated with  $H_2/20\%$  Pd(OH)<sub>2</sub>-C on 25 and 26 to give single isomers of (-)-deoxoprosophylline (1) and (+)-2-epidexoprosopinine (3) in a good overall yield of 33% and 17%, respectively. The spectral data of the synthesized compounds 1 and 3 were in absolute agreement with the reported data of the respective molecules.  $^{8f,12}$ 

Finally, syntheses of 3-hydroxypipecolic acids are shown in Scheme 4. Synthesis again starts with Perlin hydrolysis derived aldehydes. Thus, reduction of *trans* enals 15 and 16 with NaBH<sub>4</sub>–CeCl<sub>3</sub>·7H<sub>2</sub>O under Luche conditiosn<sup>25</sup> gave the diols 27 and 28 in good yields. Chemoselective saturation of the double bonds of 27 and 28 was carried out under  $H_2/$ Pd-C conditions to give 29 and 30 in 77% and 73% yields respectively. Mesylation of the free hydroxyl group of 29 and 30 using mesyl chloride and Et<sub>3</sub>N gave the mesylates 31 and 32, respectively, in excellent yields, and the products were characterized by the presence of mesyl peaks as a singlet at  $\delta$ 2.99 in their <sup>1</sup>H NMR spectra. The so-formed dimesylate derivatives were then subjected to cyclization with neat benzylamine at 90 °C to give the cyclized derivatives 33 and 34 by intermolecular followed by intramolecular nucleophilic substitution reactions. Debenzylation and in situ Boc protection gave the piperidines 35 and 36 in 87% and 89% yields, respectively. The spectral data of synthesized

SCHEME 4. Synthesis of 3-Hydroxypipecolic Acids



molecules were in absolute match with the reported data.<sup>20b,26</sup> Conversion of compounds **35** and **36** into the target molecules was performed using literature method.<sup>15</sup>

In conclusion, we have developed new synthetic routes to the synthesis of (–)-deoxoprosophylline, (+)-2-*epi*-deoxoprosopinine, and 3-hydroxypipecolic acids by utilizing the sugar-derived chiral starting materials.

## **Experimental Section**

(-)-Deoxoprosophylline (1). To a solution of azido ketone 25 in EtOH (5 mL) and concd HCl (0.25 mL) was added Pd(OH)<sub>2</sub>/ C (100 mg), and the resulting mixture was stirred under 1 atm hydrogen for 36 h. After completion of the reaction, catalyst was removed by filtration over Celite and washed with ethyl acetate (10 mL). The combined organic layer was concentrated in vacuo. The residue was dissolved in water (5 mL) and extracted once with ether (5 mL). The aqueous layer was made alkaline with 1 N NaOH and extracted thoroughly with CHCl<sub>3</sub> (3  $\times$ 5 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The white solid was recrystallized from acetone to give (-)-deoxoprosophylline (1) (46 mg, 80%): mp 89–90 °C (from acetone);  $[\alpha]^{28}_{D} = -10.7 (c \, 0.2, \text{CHCl}_3)$  [lit.<sup>8b</sup> mp 91–91.5 °C;  $[\alpha]^{28}{}_{D} = -10.3$  (*c* 0.1 CHCl<sub>3</sub>)]; IR (neat film) 3443, 3250, 2922, 2850, 1090, 1020 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ 0.86 (t, J = 6.9 Hz, 3H), 1.29 (br s, 22H), 1.33-1.49 (m, 2H), 1.63-1.67 (m, 1H), 1.91 (s, 3H), 2.08-2.12 (m, 1H), 2.64-2.66 (m, 1H), 2.76-2.78 (m, 1H), 3.76 (dt, J = 4.6 Hz, J = 10.7 Hz, 1H), 3.80 (dd, J = 2.2 Hz, J = 12.6 Hz, 1H), 4.0 (dd, J = 2.3 Hz, J = 12.6 Hz, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ 14.1, 22.6, 24.2, 25.8, 28.3, 29.3, 29.4 (2C), 29.5, 29.6, 29.7, 31.8, 32.2, 33.4, 57.3, 59.1, 63.8, 65.2; HRMS calcd for C<sub>18</sub>H<sub>38</sub>NO<sub>2</sub>  $[M + H]^+$  300.2903, found 300.2902.

(+)-2-*epi*-Deoxoprosopinine (3). The same procedure as used for (-)-deoxoprosophylline was adopted for the synthesis of (+)-2-*epi*-deoxoprosopinine: yield 47 mg, 82%; colorless solid; mp 57–58 °C (from acetone);  $[\alpha]^{28}_{D} = +3.3$  (*c* 0.6, MeOH) [lit.<sup>26</sup> mp 59 °C;  $[\alpha]^{28}_{D} = +3.0$  (*c* 0.6 MeOH)]; IR (neat film) 3340, 3259, 2922, 2853, 1092, 1018 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.88 (t, J = 6.6 Hz, 3H), 1.25 (br s, 22H), 1.53–1.57 (m, 2H), 1.75–1.80 (m, 2H), 1.96–2.05 (m, 3H), 2.83–2.85 (m, 1H), 2.96 (br s, 1H), 3.89–3.99 (m, 2H), 4.07–4.09 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  14.2, 22.7, 24.7, 25.6, 29.2–30.2 (7C), 31.1, 32.0, 37.1, 57.4, 61.0, 63.4, 65.9; HRMS calcd for C<sub>18</sub>H<sub>38</sub>NO<sub>2</sub> [M + H]<sup>+</sup> 300.2903, found 300.2906.

<sup>(24)</sup> Loiseleur, O.; Ritson, D.; Nina, M.; Crowley, P.; Wagner, T.; Hanessian, S. J. Org. Chem. 2007, 72, 6353.

<sup>(25) (</sup>a) Gemal, A. L.; Luche, J. L. J. Am. Chem. Soc. **1981**, 103, 5454. (b) Sagar, R.; Reddy, L. V. R.; Shaw, A. K. Tetrahedron: Asymmetry **2006**, 17, 1189.

<sup>(26)</sup> Kumar, P. S.; Kumar, G. D. K.; Baskaran, S. Eur. J. Org. Chem. 2008, 6063.

(2S,3R)-tert-Butyl-3-hydroxy-2-(hydroxymethyl)piperidine-1-carboxylate (35). To a solution of piperidine 33 (150 mg, 0.374 mmol) and Boc<sub>2</sub>O (163 mg, 0.748 mmol) in dry methanol was added 10% Pd(OH)<sub>2</sub>/C (150 mg) in one portion. The resulting mixture was stirred under 1 atm of hydrogen for 48 h. After completion of reaction, the catalyst was removed by filtration over Celite and washed with ethyl acetate (10 mL). The combined organic layer was concentrated in vacuo. The residue was purified by column chromatography (EtOAc/MeOH = 9:1) to yield **35** (75 mg, 87%): colorless oil;  $[\alpha]^{28}{}_{\rm D} = +15.0$  (*c* 0.4, CH<sub>2</sub>Cl<sub>2</sub>); IR (neat film) 3391, 2929, 2858, 1664, 1251, 1172, 147, 996 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  1.44 (m, 10H), 1.66-1.73 (m, 2H), 1.79-1.85 (m, 1H), 2.88-2.97 (m, 1H), 3.10 (br s, 1H), 3.13 (br s, 1H), 3.64–3.70 (m, 2H), 3.81–3.83 (m, 1H), 3.93–3.94 (m, 1H), 4.08–4.12 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 19.4, 27.0, 28.3, 40.6, 59.9, 60.4, 64.9, 80.2, 156.6; HRMS calcd for  $C_{11}H_{21}NNaO_4 [M + Na]^+ 254.1368$ , found 254.1369.

(2*S*,3*S*)-*tert*-Butyl-3-hydroxy-2-(hydroxymethyl)piperidine-1carboxylate (36). The same procedure as used to obtain 35 was utilized for the synthesis of **36**: yield 47 mg, 84%, as an oil;  $[\alpha]^{28}{}_{\rm D} = +13$  (*c* 0.45, MeOH); IR (neat film) 3372, 2932, 1666, 1178, 1072, 996 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  1.45 (s, 10H), 1.55–1.63 (m, 1H), 1.67–1.70 (m, 1H), 1.83 (dd, J = 3.8 Hz, J = 12.6 Hz, 1H), 2.77 (br s, 1H), 3.55 (br s, 1H), 3.67–3.91 (m, 4H), 4.09 (dd, J = 6.85 Hz, J = 11.4 Hz 1H), 4.44 (dd, J = 6.4 Hz, J = 12.3 Hz, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  23.7, 28.2, 28.3, 39.5, 55.9, 59.2, 69.3, 80.3, 155.6; HRMS calcd for C<sub>11</sub>H<sub>21</sub>NNaO<sub>4</sub> [M + Na]<sup>+</sup> 254.1368, found 254.1369.

Acknowledgment. We thank the Council of Scientific and Industrial Research, New Delhi, for financial support [Grant No. 01(2298)/09/EMR-II]. H.P.K., R.L., and P.K.K. thank the CSIR, New Delhi, for senior research fellowships.

Supporting Information Available: General experimental methods and <sup>1</sup>H and <sup>13</sup>C NMR spectra for compounds 1, 3, 17-26, and 29-36. This material is available free of charge via the Internet at http://pubs.acs.org.